Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
Condition: Thyroid Cancer Intervention: Drug: dabrafenib and trametinib Sponsors: National University Hospital, Singapore; Singapore General Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Hospitals | Research | Singapore Health | Thyroid | Thyroid Cancer